Beneficial Ownership Report · SCHEDULE 13G/A
X4 Pharmaceuticals, Inc.
XFORNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- X4 Pharmaceuticals, Inc.
- Company CIK
- 0001501697
- Street
- 61 North Beacon Street, 4th Floor
- City
- Boston
- State / country code
- MA
- Postal code
- 02134
Statement details
- Amendment number
- 1
- Security class
- Common Stock, $0.001 par value per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Venrock Healthcare Capital Partners III, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 2
- Name
- VHCP Co-Investment Holdings III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 3
- Name
- Venrock Healthcare Capital Partners EG, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 4
- Name
- VHCP Management III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 5
- Name
- VHCP Management EG, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 6
- Name
- Nimish Shah
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Reporting person 7
- Name
- Bong Y. Koh
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 7,644,072.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 7,644,072.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 7,644,072.00
Item 1
Issuer
X4 Pharmaceuticals, Inc.
Principal executive office address
61 North Beacon Street, 4th Floor, Boston, MA, 02134.
Item 2
Citizenship
All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.
Principal business or residence address
New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
Item 3
Not applicable indication
Y
Item 4
Percent of class
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 100,903,502 shares of common stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 4, 2026.
Amount beneficially owned
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 3,502,608 shares of common stock held by VHCP III; (ii) 350,567 shares of common stock held by VHCP Co-Investment III; and (iii) 3,790,897 shares of common stock held by held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
Sole voting power
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared voting power
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Sole dispositive power
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared dispositive power
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24.1 Power of Attorney for Bong Y. Koh (incorporated by reference to Exhibit 24.1 to the Reporting Persons' Schedule 13G filed with the SEC on September 21, 2026). Exhibit 24.2 Power of Attorney for Nimish P. Shah (incorporated by reference to Exhibit 24.2 to the Reporting Persons' Schedule 13G filed with the SEC on September 21, 2026). Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on September 21, 2026).
Signature 1
- Reporting person
- Venrock Healthcare Capital Partners III, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 2
- Reporting person
- VHCP Co-Investment Holdings III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 3
- Reporting person
- Venrock Healthcare Capital Partners EG, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 4
- Reporting person
- VHCP Management III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 5
- Reporting person
- VHCP Management EG, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 6
- Reporting person
- Nimish Shah
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Signature 7
- Reporting person
- Bong Y. Koh
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Company context
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain
Current securities
Recent company filings
- 10-Q filingNov 4, 2026
- Other EventsOct 29, 2026
- 4 filingOct 19, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 8, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding X4 Pharmaceuticals, IncOct 7, 2026